Compare ARWR & GTLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARWR | GTLS |
|---|---|---|
| Founded | 2003 | 1859 |
| Country | United States | United States |
| Employees | N/A | 11777 |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 10.0B |
| IPO Year | 2009 | N/A |
| Metric | ARWR | GTLS |
|---|---|---|
| Price | $82.73 | $208.91 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 8 |
| Target Price | $83.40 | ★ $205.67 |
| AVG Volume (30 Days) | ★ 1.7M | 1.1M |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 99.80 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $16,142,321.00 | N/A |
| Revenue This Year | N/A | $14.31 |
| Revenue Next Year | N/A | $5.89 |
| P/E Ratio | ★ N/A | $240.25 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.30 | $163.04 |
| 52 Week High | $84.55 | $209.13 |
| Indicator | ARWR | GTLS |
|---|---|---|
| Relative Strength Index (RSI) | 62.81 | 61.65 |
| Support Level | $70.05 | $206.59 |
| Resistance Level | $83.40 | $208.95 |
| Average True Range (ATR) | 4.01 | 0.73 |
| MACD | 0.37 | 0.18 |
| Stochastic Oscillator | 88.90 | 95.52 |
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
Chart Industries provides a variety of cryogenic equipment for storage, distribution, and other processes within the industrial gas and liquefied natural gas industries. It also provides natural gas processing solutions for the natural gas industry and specialty products that serve a variety of spaces, including hydrogen, biofuels, cannabis, and water treatment. The firm acquired Howden in a significant deal in early 2023, roughly doubling the size of the company. It plans to merge with Flowserve by the end of 2025.